You are now viewing 1 - 10 of 171 results
September 18, 2013 | New Public Health Post
Just before the ASTHO annual meeting began, NewPublicHealth spoke with Terry Cline, PhD, about the scope of the issue of prescription drug abuse and steps he will introduce to help reduce this public health crisis.
May 17, 2013 | Journal Article
What constitutes an innovative drug? These authors conducted a study on transformative drug development, involving 184 expert U.S. physicians across 15 medical specialties to help answer this question.
October 12, 2012 | Story
Drug patent reform and legal restrictions on pharmaceutical company advertising are explored in an RWJF Investigator’s latest research.
October 10, 2012 | Journal Article
This article examines how secondary patents can extend market exclusivity and thus delay generic competition.
October 8, 2012 | Journal Article
Under FDA policy, communications by prescription drug manufacturers must be backed by “substantial evidence” from “adequate and well-controlled investigations.” But numerous exceptions permit manufacturer promotion based on data other than randomized trials.
October 4, 2012 | Journal Article
This perspective examines the Food and Drug Administration (FDA) Safety and Innovation Act (FDASIA) of 2012.
October 1, 2012 | Journal Article
This study examines how different drug plan benefit and formulary designs influence the selection of generic drugs to treat high cholesterol among Medicare beneficiaries.
August 1, 2012 | Journal Article
While the 1983 Orphan Drug Act led to a boom in development and production of orphan drugs, inattentive regulatory standards may imperil patients with rare diseases.
May 1, 2012 | Journal Article
Value-based insurance design bases cost sharing on a medication's clinical value, not its price. This study shows the effectiveness of value-based insurance design.
December 1, 2011 | Journal Article
Study found use of free drug samples widespread among older adults but participation in pharmaceutical industry-sponsored patient assistance programs very low.